Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2011

Tanaka Makito, Butler Marcus O, Ansén Sascha, Imataki Osamu, Berezovskaya Alla, Nadler Lee M, Hirano Naoto

Abstract excerpt

PURPOSE: In previous cancer vaccine clinical trials targeting survivin, induction of specific CD8(+) T-cell responses did not consistently lead to clinical responses. Considering the critical role of CD4(+) T-cell help in generating antitumor immunity, integration of anti-survivin CD4(+) T-cell responses may enhance the efficacy of anti-survivin cancer immunotherapy. Human leukocyte antigen (HLA)-DP4 is emerging...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigen-Presenting Cells
Share to B7-1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD83 Antigen

Share to HLA-DP beta-Chains

Share to Inhibitor of Apoptosis Proteins

Share to K562 Cells

Share to Survivin

Share to Viral Matrix Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 21705450
DOI: 10.1158/1078-0432.CCR-10-3083
PMCID: PMC3156899

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell.PMID 21705450Read ↗

A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles.Semantic proximity Read ↗

Cancer Vaccines: Recent Insights and Future DirectionsSemantic proximity Read ↗

A Peptide-Based Neoantigen Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard TreatmentSemantic proximity Read ↗

Cancer Vaccines: Antigen Selection StrategySemantic proximity Read ↗

Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles.Semantic proximity Read ↗

HLA-B35-restricted immune responses against survivin in cancer patients.Semantic proximity Read ↗

Overcoming tolerance to tumour-antigens using molecularly informed epitope-modification to expand restructured oligoclonal CD4+ T-cell responsesSemantic proximity Read ↗

Generation of multiple peptide cocktail-pulsed dendritic cells as a cancer vaccine.Semantic proximity Read ↗

Human cell-based artificial antigen-presenting cells for cancer immunotherapy.Semantic proximity Read ↗

Identification of peptide-specific TCR genes by in vitro peptide stimulation and CDR3 length polymorphism analysis.Semantic proximity Read ↗

Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells.Semantic proximity Read ↗

Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.